Uber Faces Robotaxi Reckoning as Waymo's 450,000 Weekly Rides Loom Over Q4 Earnings
Uber reports Q4 2025 earnings Wednesday with analysts expecting $14.28B revenue amid growing pressure from Waymo's explosive robotaxi growth.
TRENDING TOPICS
3055 articles found for "investing"
Uber reports Q4 2025 earnings Wednesday with analysts expecting $14.28B revenue amid growing pressure from Waymo's explosive robotaxi growth.
AMD reports Q4 2025 results after market close Tuesday as investors assess whether the chipmaker can narrow Nvidia's AI dominance with its Instinct accelerators.
Alphabet and Amazon report Q4 earnings Wednesday and Thursday as investors scrutinize whether their combined $240 billion in AI capital spending is generating returns.
Ten Merck senior executives coordinated a $16 million stock purchase just days before Q4 2025 earnings, with CEO Robert Davis leading at $5.1 million in one of pharma's largest insider buying sprees.
Palantir raises 2026 revenue guidance to $7.2 billion, nearly $1 billion above consensus, as U.S. commercial revenue surges 137% and the AI data analytics giant projects 61% growth.
The 30-year Treasury yield nears 5% and the 10-year climbs to 4.28% as stronger-than-expected ISM manufacturing data reshapes Fed rate cut expectations.
PayPal reports Q4 2025 earnings as the fintech pioneer fights to prove its turnaround strategy can compete against Apple Pay, Stripe, and rising BNPL rivals.
U.S. stock futures point higher as the S&P 500 looks to reclaim the 7,000 milestone, supported by strong earnings and stabilizing commodity markets.
MSCI Asia Pacific Index jumps 2.4% as South Korea's Kospi surges 5.1%, led by Samsung and SK Hynix, marking the strongest regional rebound since Trump's tariff shock.
Tuesday brings a key test for consumer and tech stocks as PepsiCo, Chipotle, AMD, PayPal, and Merck report earnings during the busiest week of Q4 2025 reporting season.
CME Group announced its second margin increase in three days for gold, silver, platinum, and palladium futures as the exchange moves to contain the historic precious metals rout.
The FDA extended its review of Eli Lilly's oral obesity drug orforglipron to April 10, 2026, marking another delay for the troubled National Priority Voucher program.